The challenges of multi-drug-resistance in hepatology - PubMed (original) (raw)
Review
. 2016 Nov;65(5):1043-1054.
doi: 10.1016/j.jhep.2016.08.006. Epub 2016 Aug 17.
Affiliations
- PMID: 27544545
- DOI: 10.1016/j.jhep.2016.08.006
Review
The challenges of multi-drug-resistance in hepatology
Javier Fernández et al. J Hepatol. 2016 Nov.
Abstract
Antimicrobial resistance has become a major global public health security problem that needs coordinated approaches at regional, national and international levels. Antibiotic overuse and the failure of control measures to prevent the spread of resistant bacteria in the healthcare environment have led to an alarming increase in the number of infections caused by resistant bacteria, organisms that resist many (multi-drug and extensively drug-resistant strains), if not all (pan-drug-resistant bacteria) currently available antibiotics. While Gram-positive cocci resistance (methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci) shows a heterogeneous geographical distribution, extended-spectrum β-lactamase-producing Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae have become pandemic worldwide and endemic in some parts of the world, respectively. Moreover, currently available therapeutic options for resistant bacteria are very limited, with very few new agents in development. Antimicrobial resistance is especially relevant in decompensated cirrhosis. Firstly, cirrhotic patients are highly susceptible to develop infections caused by resistant bacteria as risk factors of multiresistance concentrate in this population (mainly repeated hospitalizations and antibiotic exposure). Secondly, inappropriate empirical antibiotic schedules easily translate into increased morbidity (acute kidney injury, acute-on-chronic liver failure, septic shock) and hospital mortality in advanced cirrhosis. Therefore, hepatologists must face nowadays a complex clinical scenario that requires new empirical antibiotic strategies that may further spread resistance. Global, regional and local preventive measures should therefore be implemented to combat antimicrobial resistance in cirrhosis including the restriction of antibiotic prophylaxis to high-risk populations, investigation on non-antibiotic prophylaxis, stewardship programs on adequate antibiotic prescription and on increasing awareness of the problem among health professionals, and well-defined early de-escalation policies based on rapid microbiological diagnostic tests. Other infection control practices such as hand hygiene and barrier precautions are also important. Clinical impact and cost-effectiveness of epidemiological surveillance programs (periodic rectal and nasal swabs) should also be explored.
Keywords: Antibiotic prescriptions; Antimicrobial resistance; De-escalation; Epidemiological surveillance; Extensively drug-resistant; Mortality; Multi-drug-resistance; New antibiotics; Pan-drug-resistance; Prevention; Prognosis; Stewardship programs.
Copyright © 2016. Published by Elsevier B.V.
Similar articles
- New antibiotic strategies in patients with cirrhosis and bacterial infection.
Fernández J, Acevedo J. Fernández J, et al. Expert Rev Gastroenterol Hepatol. 2015;9(12):1495-500. doi: 10.1586/17474124.2015.1100075. Epub 2015 Oct 14. Expert Rev Gastroenterol Hepatol. 2015. PMID: 26465070 Review. - Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.
Fernández J, Prado V, Trebicka J, Amoros A, Gustot T, Wiest R, Deulofeu C, Garcia E, Acevedo J, Fuhrmann V, Durand F, Sánchez C, Papp M, Caraceni P, Vargas V, Bañares R, Piano S, Janicko M, Albillos A, Alessandria C, Soriano G, Welzel TM, Laleman W, Gerbes A, De Gottardi A, Merli M, Coenraad M, Saliba F, Pavesi M, Jalan R, Ginès P, Angeli P, Arroyo V; European Foundation for the Study of Chronic Liver Failure (EF-Clif). Fernández J, et al. J Hepatol. 2019 Mar;70(3):398-411. doi: 10.1016/j.jhep.2018.10.027. Epub 2018 Nov 2. J Hepatol. 2019. PMID: 30391380 - Management of infections in patients with cirrhosis in the context of increasing therapeutic resistance: A systematic review.
Allaire M, Cadranel JF, Nguyen TTN, Garioud A, Zougmore H, Heng R, Perignon C, Ollivier-Hourmand I, Dao T. Allaire M, et al. Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):264-274. doi: 10.1016/j.clinre.2019.10.003. Epub 2019 Nov 6. Clin Res Hepatol Gastroenterol. 2020. PMID: 31706985 - Emerging antibiotic resistance: carbapenemase-producing enterobacteria. Bad new bugs, still no new drugs.
Spera AM, Esposito S, Pagliano P. Spera AM, et al. Infez Med. 2019 Dec 1;27(4):357-364. Infez Med. 2019. PMID: 31846984 Review. - The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey.
Merli M, Lucidi C, Di Gregorio V, Falcone M, Giannelli V, Lattanzi B, Giusto M, Ceccarelli G, Farcomeni A, Riggio O, Venditti M. Merli M, et al. PLoS One. 2015 May 21;10(5):e0127448. doi: 10.1371/journal.pone.0127448. eCollection 2015. PLoS One. 2015. PMID: 25996499 Free PMC article.
Cited by
- Guidelines for Antibiotics Prescription in Critically Ill Patients.
Khilnani GC, Tiwari P, Mittal S, Kulkarni AP, Chaudhry D, Zirpe KG, Todi SK, Mohan A, Hegde A, Jagiasi BG, Krishna B, Rodrigues C, Govil D, Pal D, Divatia JV, Sengar M, Gupta M, Desai M, Rungta N, Prayag PS, Bhattacharya PK, Samavedam S, Dixit SB, Sharma S, Bandopadhyay S, Kola VR, Deswal V, Mehta Y, Singh YP, Myatra SN. Khilnani GC, et al. Indian J Crit Care Med. 2024 Aug;28(Suppl 2):S104-S216. doi: 10.5005/jp-journals-10071-24677. Epub 2024 Aug 10. Indian J Crit Care Med. 2024. PMID: 39234229 Free PMC article. - Bacterial Infections in Acute-on-chronic Liver Failure: Epidemiology, Diagnosis, Pathogenesis, and Management.
Xu Z, Zhang X, Chen J, Shi Y, Ji S. Xu Z, et al. J Clin Transl Hepatol. 2024 Jul 28;12(7):667-676. doi: 10.14218/JCTH.2024.00137. Epub 2024 Jun 20. J Clin Transl Hepatol. 2024. PMID: 38993512 Free PMC article. Review. - Multidrug-resistant bacterial infections in the liver transplant setting.
Ferrarese A, Senzolo M, Sasset L, Bassi D, Cillo U, Burra P. Ferrarese A, et al. Updates Surg. 2024 Jun 25. doi: 10.1007/s13304-024-01903-6. Online ahead of print. Updates Surg. 2024. PMID: 38918314 Review. - Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.
Odenwald MA, Lin H, Lehmann C, Dylla NP, Cole CG, Mostad JD, Pappas TE, Ramaswamy R, Moran A, Hutchison AL, Stutz MR, Dela Cruz M, Adler E, Boissiere J, Khalid M, Cantoral J, Haro F, Oliveira RA, Waligurski E, Cotter TG, Light SH, Beavis KG, Sundararajan A, Sidebottom AM, Reddy KG, Paul S, Pillai A, Te HS, Rinella ME, Charlton MR, Pamer EG, Aronsohn AI. Odenwald MA, et al. Nat Microbiol. 2023 Nov;8(11):2033-2049. doi: 10.1038/s41564-023-01493-w. Epub 2023 Oct 16. Nat Microbiol. 2023. PMID: 37845315 Free PMC article. - Norfloxacin versus alternative antibiotics for prophylaxis of spontaneous bacteria peritonitis in cirrhosis: a systematic review and meta-analysis.
Song S, Yang Y, Geng C, Tang Z, Wang C, Li X. Song S, et al. BMC Infect Dis. 2023 Aug 28;23(1):557. doi: 10.1186/s12879-023-08557-6. BMC Infect Dis. 2023. PMID: 37641014 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources